April 28, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Celladon Corp (NASDAQ:CLDN) shares over potential securities laws violations by Celladon and certain of its directors and officers in connection certain financial statements was announced.

Shares of Celladon Corp (NASDAQ:CLDN) declined from over $27 per share in March to as low as $2.59 per share during April 27, 2015.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Celladon Corp (NASDAQ:CLDN) concerning whether a series of statements by Celladon Corp (NASDAQ:CLDN regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Celladon Corp (NASDAQ:CLDN) grew from $9.40 per share in October 2014 to as high as $27.26 per share in March 2015.

Then on April 26, 2015 Celladon Corp reported negative results for CUPID2 trial of MYDICAR(R) in advanced heart failure. Celladon Corp said that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints.
Shares of Celladon Corp (NASDAQ:CLDN) declined from as high as $14.36 per share on April 24, 2015 to as low as $2.59 per share on April 27, 2015.